Tags

Type your tag names separated by a space and hit enter

[Immunogenicity, efficacy and reactogenicity of a human diploid cell strain (HDCS) rabies vaccine in man; recommendations for pre- and post-exposure application (vaccination scheme) (author's transl)].
Med Klin. 1977 May 06; 72(18):797-805.MK

Abstract

Since 1973 a total of 365 individuals between 4 and 74 years of age were vaccinated with the HDCS-rabies-vaccine produced by Mérieux/Lyon. Only minor local side reactions were observed in some patients. No adverse systemic reactions due to the vaccine occurred in any of the vaccinees. Seroconversion was observed in 100% of the vaccinated subjects. Neutralizing antibodies could be demonstrated in all 365 vaccinees in titers ranging from 1:10 to 1:2238 (0.35 to 72.5 I.U) employing 200 LD 50 of rabies virus in the mouse neutralization test. The persistence of antibodies has been followed up for 2 years. The efficacy of the HDCS-vaccine in post-exposure treatment proved to be reliable. Sixteen patients suffered bites, scratches, cuts und abrasions by proven rabid animals. Another 8 patients had come into close contact with saliva of confirmed rabid animals. None of these patients developed clinical rabies during an observation period now covering 1-3 years. The HDCS-rabies-vaccine, thus, proved to be well tolerated, innocuous and highly protective. Under those aspects, this vaccine must be considered superior to the duck-embryo-vaccine currently licensed in Germany and should be preferred for propylactic and post-exposure vaccination as well. The postexposure schedule elaborated in our laboratory has been adopted and recommended by a WHO expert group on rabies. The data presented here constitute the first report on post-exposure application of HDCS-rabies-vaccine in man.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

ger

PubMed ID

865381

Citation

Kuwert, E K., et al. "[Immunogenicity, Efficacy and Reactogenicity of a Human Diploid Cell Strain (HDCS) Rabies Vaccine in Man; Recommendations for Pre- and Post-exposure Application (vaccination Scheme) (author's Transl)]." Medizinische Klinik, vol. 72, no. 18, 1977, pp. 797-805.
Kuwert EK, Marcus I, Höher PG, et al. [Immunogenicity, efficacy and reactogenicity of a human diploid cell strain (HDCS) rabies vaccine in man; recommendations for pre- and post-exposure application (vaccination scheme) (author's transl)]. Med Klin. 1977;72(18):797-805.
Kuwert, E. K., Marcus, I., Höher, P. G., Werner, J., Iwand, A., & Helm, E. B. (1977). [Immunogenicity, efficacy and reactogenicity of a human diploid cell strain (HDCS) rabies vaccine in man; recommendations for pre- and post-exposure application (vaccination scheme) (author's transl)]. Medizinische Klinik, 72(18), 797-805.
Kuwert EK, et al. [Immunogenicity, Efficacy and Reactogenicity of a Human Diploid Cell Strain (HDCS) Rabies Vaccine in Man; Recommendations for Pre- and Post-exposure Application (vaccination Scheme) (author's Transl)]. Med Klin. 1977 May 6;72(18):797-805. PubMed PMID: 865381.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Immunogenicity, efficacy and reactogenicity of a human diploid cell strain (HDCS) rabies vaccine in man; recommendations for pre- and post-exposure application (vaccination scheme) (author's transl)]. AU - Kuwert,E K, AU - Marcus,I, AU - Höher,P G, AU - Werner,J, AU - Iwand,A, AU - Helm,E B, PY - 1977/5/6/pubmed PY - 2000/3/22/medline PY - 1977/5/6/entrez SP - 797 EP - 805 JF - Medizinische Klinik JO - Med Klin VL - 72 IS - 18 N2 - Since 1973 a total of 365 individuals between 4 and 74 years of age were vaccinated with the HDCS-rabies-vaccine produced by Mérieux/Lyon. Only minor local side reactions were observed in some patients. No adverse systemic reactions due to the vaccine occurred in any of the vaccinees. Seroconversion was observed in 100% of the vaccinated subjects. Neutralizing antibodies could be demonstrated in all 365 vaccinees in titers ranging from 1:10 to 1:2238 (0.35 to 72.5 I.U) employing 200 LD 50 of rabies virus in the mouse neutralization test. The persistence of antibodies has been followed up for 2 years. The efficacy of the HDCS-vaccine in post-exposure treatment proved to be reliable. Sixteen patients suffered bites, scratches, cuts und abrasions by proven rabid animals. Another 8 patients had come into close contact with saliva of confirmed rabid animals. None of these patients developed clinical rabies during an observation period now covering 1-3 years. The HDCS-rabies-vaccine, thus, proved to be well tolerated, innocuous and highly protective. Under those aspects, this vaccine must be considered superior to the duck-embryo-vaccine currently licensed in Germany and should be preferred for propylactic and post-exposure vaccination as well. The postexposure schedule elaborated in our laboratory has been adopted and recommended by a WHO expert group on rabies. The data presented here constitute the first report on post-exposure application of HDCS-rabies-vaccine in man. SN - 0025-8458 UR - https://www.unboundmedicine.com/medline/citation/865381/[Immunogenicity_efficacy_and_reactogenicity_of_a_human_diploid_cell_strain__HDCS__rabies_vaccine_in_man L2 - http://www.diseaseinfosearch.org/result/6131 DB - PRIME DP - Unbound Medicine ER -